Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine versus fentanyl + midazolam for stress response attenuation during microlaryngoscopy
IRCT20210117050057N2Phase 3Completed
- Sponsor
- Magrabi Hospitals & Centers
- Start
- Mar 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dexmedetomidine, fentanyl and midazolam in microlaryngoscopy (2 arms), sponsored by Magrabi Hospitals & Centers. Primary endpoint: Hemodynamic stress response. Started Mar 2021; status: completed.
02
Drugs
dexmedetomidinefentanylmidazolam
03
Conditions
microlaryngoscopy
Beyond the preview
Go deeper on IRCT20210117050057N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210117050057N2.